Pacific Edge Limited (NZE: PEB)

Market Cap	50.34M
Revenue (ttm)	22.62M
Net Income (ttm)	-28.79M
Shares Out	811.92M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,259,821
Average Volume	2,984,841
Open	0.0620
Previous Close	0.0620
Day's Range	0.0590 - 0.0620
52-Week Range	0.0500 - 0.1850
Beta	1.07
RSI	32.40
Earnings Date	Feb 25, 2025

About Pacific Edge

Pacific Edge Limited, a cancer diagnostics company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have ...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2001
• Employees: 114
• Stock Exchange: New Zealand Stock Exchange
• Ticker Symbol: PEB

Financial Performance

In 2023, Pacific Edge's revenue was 25.23 million, an increase of 19.95% compared to the previous year's 21.03 million. Losses were -29.54 million, 9.53% more than in 2022.